pharmaphorum

MARCH 21, 2022

Designed for experts working directly on myeloid-directed therapies, and those in adjacent immuno-oncology fields, from cell therapy to checkpoint and engager development.

Clinical Development 52

Clinical Development Development 52

pharmaphorum

APRIL 30, 2021

A recent analysis delves into the challenges companies face in getting digital health technologies reimbursed and presents recommendations for how they can find a smoother path to market. Experts from ICON give us their views on the past, present and future of NICE’s standing on the world stage. Time for a NICE change.

Marketing 98

Marketing Sales Regulation Drugs 98

pharmaphorum

SEPTEMBER 22, 2022

Read on to find out about unlocking the potential of connected commercialisation solutions, what HCPs want from post-pandemic communication, achieving launch excellence in oncology and much more. Achieving launch excellence in oncology. A successful launch in the oncology space is not guaranteed; it is strategically planned and earned.

Gene Therapy 52

Gene Therapy Marketing Gene Sales 52

pharmaphorum

DECEMBER 7, 2022

Having recently assessed the relationship between drug price and prevalence of non-oncology rare diseases, CRA’s Life Sciences Practice team explores in greater depth the situation for these orphan drugs in France in this final article of a three-part series. Source: CRA analysis). Relationship between ATC and eligible patient number.

Drugs 104

Drugs Life Science Production Manufacturing 104

pharmaphorum

DECEMBER 2, 2022

Read on for key stories from this year’s Frontiers Health conference in Italy, unlocking the promise of patient support programmes in oncology, supercharging communications with modular content, and much more. Unlocking the promise of patient support programmes in oncology. A history of medical imaging. Company profile: Vinehealth.

Pharma Companies 52

Pharma Companies Vaccination Vaccine Marketing 52

Camargo

MAY 10, 2021

Yet many, including the FDA’s top oncology drug reviewers, have found that the Agency has not taken action to remove products from the market or withdraw indications when these confirmatory trials have failed to show benefit. head of the FDA’s Oncology Center of Excellence, and Julia Beaver, M.D.,

Development 185

Development Clinical Trials Clinical Trials Trials 185

The Pharma Data

OCTOBER 18, 2020

The abstract presents the 12-month analysis of biomarkers and clinical outcome from the phase I/II trial in malignant pleural mesothelioma where ONCOS-102 is added to standard of care chemotherapy (pemetrexed / cisplatin). This analysis supports the data presented in June. View original content: [link]. OSLO, Norway , Oct.

Trials 40

Trials Development 40

pharmaphorum

MAY 6, 2022

Combination pricing: access to the future of oncology treatment. pharmaphorum’s digital magazine Deep Dive provides objective, issue-driven views, analysis, high-level interviews and unique research for pharmaceutical companies, biotech firms and the wider healthcare sector. Rethinking value: why diverse viewpoints matter.

Marketing 52

Marketing Life Science Regulation Development 52

The Pharma Data

JANUARY 17, 2021

View the full release here: [link]. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets, and advanced analytics. About Vall d’Hebron Institute of Oncology. 18, 2021 08:00 UTC. BARCELONA, Spain & REDWOOD CITY, Calif.–(

Genome 40

Genome Genomics Clinical Trials Clinical Trials 40

pharmaphorum

MARCH 16, 2022

Merck & Co’s two powerhouse oncology drugs – Keytruda and Lynparza – have failed to show efficacy when used in combination for patients with previously treated metastatic castration-resistant prostate cancer (mCRPC).

Trials 58

Trials Clinical Trials Clinical Trials Gene 58

XTalks

MARCH 19, 2024

The FDA’s Oncologic Drugs Advisory Committee (ODAC) has lent support to Johnson and Johnson’s (J&J) and Bristol Myers Squibb’s (BMS) applications for moving their myeloma CAR T-cell therapies Carvykti and Abecma, respectively, to earlier treatment lines.

Clinical Trials 59

Clinical Trials Clinical Trials Trials Immune Response 59

pharmaphorum

SEPTEMBER 17, 2020

In this issue we hear from a variety of KOLs who are leading pharma comms into a new, digital era to get their views on how pharma can best adapt for the post-COVID world. The right people and the right environment for innovative comms.

Marketing 52

Marketing Sales Research Development 52

The Pharma Data

MARCH 11, 2021

Eli Lilly and Company (NYSE: LLY) today announced that data from programs across its oncology portfolio and pipeline will be presented at the 2021 American Association for Cancer Research (AACR) Annual Meeting, to be held virtually April 10-15, 2021. Loxo Oncology at Lilly posters can also be viewed at www.loxooncology.com.

Research 52

Research Clinical Trials Clinical Trials Trials 52

The Pharma Data

OCTOBER 19, 2020

Caris’ collaborative network focused on expanding the application of precision medicine in oncology supports Winship’s enterprising approach to research leading to transformative discoveries in cancer care and treatment. MBA, FACP, Chairman of the Caris Precision Oncology Alliance. IRVING, Texas and ATLANTA , Oct.

Life Science 52

Life Science Clinical Trials Clinical Trials RNA 52

The Pharma Data

OCTOBER 18, 2020

BOSTON–( BUSINESS WIRE )– AVEO Oncology (Nasdaq: AVEO) today announced the appointment of David Crist as Vice President of Sales. David’s proven track record of success and deep experience with the launch and growth of new oncology therapies will play an important role in the success of our commercial strategy and team.

Sales 52

Sales Clinical Trials Clinical Trials Containment 52

The Pharma Data

AUGUST 3, 2021

The FDA is reviewing the application under the Real-Time Oncology Review pilot programme, which aims to explore a more efficient review process to ensure safe and effective treatments are available to patients as early as possible. 1%, as determined by an FDA-approved test. 0.88) in people with Stage II-IIIA NSCLC whose tumours express PD-L1?

HR 52

HR Antibody FDA Approval Licensing 52

pharmaphorum

FEBRUARY 26, 2021

Emma Sutcliffe from NexGen Healthcare Communications looks at how patient insights can bring the invisible challenges of living with a rare condition into plain view. Focus on Rare: the invisible burden of rare diseases. Digitalising drug discovery.

Development 58

Development Research Pharma Companies Vaccination 58

pharmaphorum

JUNE 20, 2022

Verdin and Hadjivasiliou say the calls for change are valid, though there are two ways one can view these appeals for modifications to legislation. Regarding oncology, for example, much has changed about the understanding of cancer since the Orphan Drug Act in the US was signed into law 40 years ago.

Drugs 52

Drugs Marketing Life Science Regulation 52

The Pharma Data

DECEMBER 13, 2020

The trial met its primary endpoint at a pre-specified interim analysis demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS) (P<0.05), and was stopped early because superior efficacy was demonstrated. View original content: [link]. Senhwa Biosciences, Inc. Source link.

Trials 40

Trials DNA Clinical Trials Clinical Trials 40

pharmaphorum

NOVEMBER 2, 2020

It’s time for pharma to take a 360-degree view of its clinical trial data and step into the future with near real-time study management. • Read the latest issue Deep Dive: Digital Health Innovation 2020 in full. Subscribe to future issues of Deep Dive. The post Deep Dive: Digital Health Innovation 2020 appeared first on.

Sales 58

Sales Clinical Trials Clinical Trials Marketing 58

pharmaphorum

JANUARY 22, 2021

Analysis of prescribing changes. Among HER2+ breast cancer patients in this claims analysis, there was a significant decline of about 41% in terms of the total number of claims using infusion treatment (including Enhertu, Herceptin, Herzuma, Kadcyla, Ogivri, Perjeta, and Trazimera) from oncologists from February to June 2020.

Pharmacy 104

Pharmacy Marketing Research Nurses 104

XTalks

AUGUST 5, 2020

Rosha Poudyal, PhD, Science and Technology Advisor at 10x Genomics, discussed some of the innovative single cell technology tools that the company is developing and their application in various research areas including oncology, infectious disease and immunology. Single Cell Data Analysis.

Gene Expression 112

Gene Expression Development RNA Drugs 112

pharmaphorum

DECEMBER 14, 2020

pharmaphorum’s digital magazine Deep Dive provides objective, issue-driven views, analysis, high-level interviews and unique research for pharmaceutical companies, biotech firms and the wider healthcare sector. . • Read the latest issue Deep Dive: Patients and Partnerships 2020 in full.

Clinical Trials 75

Clinical Trials Clinical Trials Trials Marketing 75

The Pharma Data

NOVEMBER 23, 2020

An 18-month analysis shows that median Overall Survival (mOS) will be at least 18.2 An analysis of all the first-line patients, including 3 experimental safety lead-in patients, shows similar results as the randomized first-line patients. The next survival analysis is planned in first half of 2021. View original content: [link].

Trials 40

Trials FDA Approval Development Drugs 40

pharmaphorum

MAY 21, 2021

Data announced ahead of this year’s American Society of Clinical Oncology (ASCO) conference suggest that Gilead and CAR-T rivals Bristol-Myers Squibb and Novartis better watch their backs as Allogene announced plans for a pivotal study this year.

Marketing 52

Marketing Trials Manufacturing Doctors 52

The Pharma Data

SEPTEMBER 28, 2021

An extended analysis of PD-L1 subgroups within the Stage II-IIIA population shows there’s a better magnitude of enjoy adjuvant Tecentriq in people with PD-L1 expression ?50%, There was no clear difference in patterns of relapse. 50%, compared with those with 1-49% PD-L1 expression.2 receptors.

Clinical Trials 52

Clinical Trials Clinical Trials Trials HR 52

The Pharma Data

OCTOBER 27, 2020

View the full release here: [link]. DXRX data and expert guided collaborations can practically unite us in eliminating those access barriers for patients and help us to further move precision oncology forward.”. View source version on businesswire.com: [link]. This press release features multimedia. Source link.

Medicine 40

Medicine Marketing Branding Genetics 40

The Pharma Data

JANUARY 13, 2021

“With the recent announcement that the RATIONALE 303 trial met its primary endpoint of overall survival at its interim analysis, three Phase 3 trials of tislelizumab in NSCLC have achieved a positive outcome at interim analysis,” commented Yong (Ben) Ben, M.D., Chief Medical Officer, Immuno-Oncology at BeiGene. v Zhang, T.,

Production 52

Production Trials Antibody Clinical Trials 52

The Pharma Data

JANUARY 26, 2021

The full data analysis on 353 subjects would be available by the end of February 2021. Within this group, there was sub group analysis carried out on 181 subjects in the low risk category. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.

Life Science 40

Life Science Production Marketing Dermatology 40

XTalks

OCTOBER 12, 2022

We [Philips Pharma Solutions, formerly BioTel Research] have successfully ran multi-site DCE-MRI trials,” said Edward Ashton, PhD, VP, Oncology Imaging, Philips Pharma Solutions. An Example of an Anti-Angiogenic Therapy in Oncology. An Example of an Anti-Vascular Therapy in Oncology. Introduction to Perfusion Imaging.

Clinical Trials 93

Clinical Trials Clinical Trials Trials Drugs 93

The Pharma Data

DECEMBER 16, 2020

The partnership leverages Evotec’s proprietary PanOmics platform, which combines enhanced throughput proteomics, high throughput transcriptomics and cell imaging with an integrated data analysis platform PanHunter. View source version on accesswire.com: [link]. 0)40.56081-775, volker.braun@evotec.com. Source link.

Protein 40

Protein Containment Bioinformatics Drugs 40

The Pharma Data

FEBRUARY 8, 2021

1] Results will be featured in an oral presentation at the American Society of Clinical Oncology’s Genitourinary (ASCO GU) Cancers Symposium, taking place virtually February 11-13, 2021 (Abstract #11; Rapid Abstract Session: Prostate Cancer, February 11, 3:30 PM-4:15 PM EST). About the TITAN Study 2.

HR 52

HR Hormones Development Production 52

The Pharma Data

NOVEMBER 8, 2020

Published in the November issue of JAMA Oncology , this is the first study to support clinical utility of CTC count in a randomized clinical trial. View original content: [link]. BOLOGNA, Italy and HUNTINGDON VALLEY, Pa. , Menarini Silicon Biosystems , based in Bologna, Italy , and Huntingdon Valley, Pa. , Source link.

Research 40

Research Hormones Clinical Trials Clinical Trials 40

The Pharma Data

DECEMBER 21, 2020

Medical Director and Head of the Immunological Tumor Group at University Medicine Halle, Germany, who is a renowned oncology clinician and researcher specializing in the analysis of immuno-oncology treatments and their interaction with tumor tissues. View source version on businesswire.com: [link]. Mascha Binder, M.D.,

Trials 52

Trials Vaccination Vaccine Clinical Trials 52

Drug Discovery World

SEPTEMBER 20, 2022

This considerable magnitude of difference in read length affords researchers a more complete and accurate view of genomic variation. In antimicrobial resistance research, scientists need continual genomic-level analysis to understand resistance and the evolution of microbes.

Gene Therapy 52

Gene Therapy Gene Genome Genomics 52

XTalks

MAY 6, 2022

The eClinical solutions team is committed to making clinical research data acquisition and analysis easy and intelligent to help bring new treatments to patients more quickly. A complete view of query and issue statuses provides clinical teams with earlier insights into potential areas that need addressing. elluminate Mapper.

Clinical Trials 98

Clinical Trials Clinical Trials Trials Life Science 98

pharmaphorum

JANUARY 27, 2023

Physicians and staff have a significant responsibility to maintain the quality of a trial through important procedures, including patient chart analysis, to grasp key insights that will have an impact on patient care decisions. The post Tackling ongoing staffing burnout rates through AI-enabled precision oncology appeared first on.

Clinical Trials 110

Clinical Trials Clinical Trials Trials Clinical Research 110